We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

New Analysis Method Detects Pathogens in Blood Faster and More Accurately by Melting DNA

By LabMedica International staff writers
Posted on 22 Feb 2024
Print article
Image: Researchers used this chip to analyze the microbes present in whole blood samples (Photo courtesy of UC San Diego)
Image: Researchers used this chip to analyze the microbes present in whole blood samples (Photo courtesy of UC San Diego)

Globally, an alarming one in every five deaths is attributed to complications related to sepsis, with children accounting for 41% of these fatalities. Common practice involves administering antibiotics to sepsis patients while waiting for blood culture results, which can contribute to antibiotic resistance. Ineffectively treating sepsis can be detrimental, as up to 30% of patients receive incorrect treatments, further elevating their risk of death. The critical nature of timely and accurate diagnosis in sepsis cases is underscored by the fact that the mortality risk escalates by 4% every hour the infection is not properly identified or treated. Now, a new analysis technique offers quicker and more precise pathogen detection in blood samples compared to traditional blood cultures, which are the standard in infection diagnosis.

The new method, called digital DNA melting analysis, has been developed by researchers at UC San Diego (La Jolla, CA, USA) and is capable of delivering results in less than six hours. This marks a significant improvement over the typical 15 hours to several days required by culture methods, depending on the pathogen involved. The process utilizes universal digital high-resolution DNA melting, involving heating DNA until it separates. Each DNA sequence reveals a unique signature during the melting process. By imaging and analyzing this process, machine learning algorithms can discern the types of DNA in the samples and identify pathogens. This method not only outpaces blood cultures in terms of speed but also has a substantially lower risk of generating false positives compared to other emerging DNA detection technologies, such as Next Generation Sequencing.

The research began with one milliliter of blood from each of 17 patients in a preliminary clinical study. These samples were collected concurrently with those for blood cultures from infants and toddlers. The researchers honed the DNA isolation process and machine learning techniques to minimize or eliminate interference from human DNA in contrast to pathogen DNA in the samples. They refined a machine learning algorithm to accurately distinguish between the melting curves of pathogens and background noise. This algorithm correlates the observed curves with a database of known DNA melt curves. Moreover, it can identify curves produced by organisms not in this database, which is particularly useful in detecting rare or emerging pathogens in a sample.

The results from this method were not only consistent with those obtained from blood cultures of the same samples, but they also did not yield any false positives. This contrasts with other tests based on nucleic acid amplification and next-generation DNA sequencing databases, which tend to amplify all present DNA, leading to false positives. Contamination from various sources such as the environment, test tubes, reagents, and skin can often lead to challenges in interpreting test results. This new method detected pathogens 7.5 hours to approximately 3 days faster than conventional blood cultures. Additionally, it provides more than just a binary positive or negative outcome; it quantifies the extent of pathogen presence in the samples. Future plans include conducting a more extensive clinical study and extending the methodology to adult patients.

“This is the first time this method has been tested on whole blood from patients suspected of having sepsis. So this study is a more realistic preview of how the technology could perform in real clinical scenarios,” said Stephanie Fraley, a professor at the UC San Diego. “We want to give doctors the ability to treat their patients based not on aggregate data, but with precise, accurate individual data, enabling truly personalized medicine.”

Related Links:
UC San Diego

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.